This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ding, Y. Articles by Yan, D.-H. Search for Related Content PubMed PubMed Citation Articles by Ding, Y. Articles by Yan, D.-H.

Interferon-Inducible Protein IFIX1 Functions as a Negative Regulator of HDM2

Department of Molecular and Cellular Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030,¹ The University of Texas, Graduate School of Biomedical Sciences at Houston, Houston, Texas,² Department of Biochemistry and Molecular Biology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239³

Received 15 July 2005/ Returned for modification 21 August 2005/ Accepted 16 December 2005

	ABSTRACT

Top Abstract Introduction Materials and Methods Results Discussion References

 
The 200-amino-acid repeat (HIN-200) gene family with the hematopoietic interferon (IFN)-inducible nuclear protein encodes highly homologous proteins involved in cell growth, differentiation, autoimmunity, and tumor suppression. IFIX is the newest member of the human HIN-200 family and is often downregulated in breast tumors and breast cancer cell lines. The expression of the longest isoform of IFIX gene products, IFIX1, is associated with growth inhibition, suppression of transformation, and tumorigenesis. However, the mechanism underlying the tumor suppression activity of IFIX1 is not well understood. Here, we show that IFIX1 downregulates HDM2, a principal negative regulator of p53, at the posttranslational level. IFIX1 destabilizes HDM2 protein and promotes its ubiquitination. The E3 ligase activity of HDM2 appears to be required for this IFIX1 effect. Importantly, HDM2 downregulation is required for the IFIX1-mediated increase of p53 protein levels, transcriptional activity, and nuclear localization, suggesting that IFIX1 positively regulates p53 by acting as a negative regulator of HDM2. We found that IFIX1 interacts with HDM2. Interestingly, the signature motif of the HIN-200 gene family, i.e., the 200-amino-acid HIN domain of IFIX1, is sufficient not only for binding HDM2 but also for downregulating it, leading to p53 activation. Finally, we show that IFIX mediates HDM2 downregulation in an IFN-inducible system. Together, these results suggest that IFIX1 functions as a tumor suppressor by repressing HDM2 function.

	INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

 
Interferons (IFNs) play an essential role in innate and adaptive immunity and the host defense system against viral, bacterial, and parasitic infections (49). Also, IFNs have been used as therapeutic agents for treating human solid and hematologic malignancies, such as hairy cell leukemia, chronic myelogenous leukemia, follicular (non-Hodgkin's) lymphoma, and malignant melanoma (34, 81). Although the mechanism of the IFN-induced antitumor activity is poorly understood, it is believed that the IFN-inducible proteins may be critical for executing tumor suppression (48). Indeed, IFN-inducible genes, such as those for RNase L (73), IFN regulatory factor 1 (67), and the double-stranded RNA-regulated serine/threonine protein kinase (PKR) (39), have been implicated in tumor suppression.

The IFN-inducible HIN-200 gene family encodes a class of proteins that share a 200-amino-acid (HIN) signature motif of type a and/or type b. Four human (IFI16, MNDA, AIM2, and IFIX) and five mouse (p202a, p202b, p203, p204, and p205 [or D3]) HIN-200 family proteins have been identified (2, 54). HIN-200 genes are located at chromosome 1q21-23 as a gene cluster in both mouse and human genomes. Most HIN-200 proteins possess two major protein domains. First, the N-terminal region of HIN-200 proteins contains a highly helical pyrin domain (PYD) (36), which belongs to the death domain-containing protein superfamily involved in apoptosis and inflammation (52, 66, 75). Second, the C-terminal HIN domain consists of two consecutive oligonucleotide/oligosaccharide-binding folds (1). The oligonucleotide/oligosaccharide-binding fold-containing proteins are involved in a variety of biological processes, including DNA replication, DNA recombination, DNA repair, and telomere maintenance (6, 78). However, the role of HIN-200 proteins in these biological processes is poorly understood.

The observations that HIN-200 proteins interact with several cellular regulators involved in cell cycle control, differentiation, and apoptosis suggest that the physiological role of HIN-200 proteins is beyond the IFN system (2, 54). Moreover, the observation that HIN-200, e.g., IFI16, is widely expressed in normal human tissues, including endothelial and epithelial cells, further supports this notion (27, 65, 83). Therefore, it is not surprising that loss or reduced expression of HIN-200 genes is associated with human cancers (3, 17-19, 26, 46, 61, 64, 80). These studies suggest that HIN-200 proteins may play a role in tumor suppression.

The mouse double-minute gene 2 (mdm2) encodes an oncoprotein (22, 24). Consistently, HDM2, the human homologue of mdm2, is found frequently overexpressed in human cancers, including about 50% of breast cancers (33, 55-57, 71). A recent report also showed that HDM2 overexpression in tumors is associated with poor prognosis (59). These results underscore the pivotal involvement of HDM2 in tumorigenesis. Therefore, HDM2 has been an important target for developing cancer therapeutics (25, 45, 72).

The RING finger domain of HDM2 possesses an intrinsic E3 ubiquitin ligase activity (42). Ubiquitinated proteins are targeted for proteasome-mediated degradation. The best-known substrate of the E3 ligase activity of HDM2 is the p53 tumor suppressor protein. HDM2 binds to the N terminus of p53. This interaction allows HDM2 to inhibit p53 in two ways: (i) blocking the ability of p53 to activate transcription of its target genes by binding to the N-terminal transactivation domain of p53 (11, 62) and (ii) mediating ubiquitination of p53, leading to degradation by proteasome (30, 31, 47). Interestingly, HDM2 is also a substrate of its own E3 ligase activity (23, 37). The intricate regulation of p53 and HDM2 is further demonstrated by the fact that HDM2 is also p53 responsive (4, 63). Thus, these two molecules link together in a negative feedback loop for the purpose of keeping the cellular p53 at low levels in the absence of stress. The p53-HDM2 autoregulatory loop is vital as demonstrated by the rescue of embryonic lethality of mdm2-null mice in a p53-null background (44, 60). Therefore, a defective autoregulatory loop caused by mutations, DNA damage, or oncogenic insult has a profound impact on tumorigenesis (16).

We recently identified IFIX as a novel member of the human HIN-200 family (18). The IFIX transcriptional unit expresses at least six IFIX isoforms. IFIX proteins are primarily nuclear and possess a single type a HIN motif. Importantly, the expression of IFIX is reduced in the majority of breast tumors and breast cancer cell lines. Therefore, IFIX may function as a putative tumor suppressor. Consistently, the expression of IFIX1, the longest IFIX isoform, leads to suppression of growth and transformation in vitro and tumorigenicity and tumor growth in vivo (18). The growth inhibitory activity of IFIX1 is associated with the induction of p21^CIP1, a key cyclin-dependent kinase inhibitor (18). However, the mechanism of the IFIX1 tumor suppressor activity has not been well elucidated. In this report, we show a novel interaction between IFIX1 and HDM2 which leads to destabilization of HDM2. Consequently, p53 is stabilized and activated. The novel cross talk between the IFN-IFIX signaling pathway and the HDM2-p53 autoregulatory loop may contribute in part to the IFN-induced antitumor activity in certain cancers.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell lines, plasmids, and reagents. MCF-7 and its FLAG-tagged IFIX1 derivatives, X-1 and X-2, as well as MDA-MB-468 and its FLAG-tagged IFIX1 derivatives, X-1 and X-2, have been described previously (18). The corresponding control cell lines are the pooled stable clones transfected with the empty vector (pCMV-Tag2B [FLAG]; Stratagene, La Jolla, CA) (18). H1299, HCT116 and its p53-null derivative, HCT116 (p53^–/–) (8), 293 and its large-T derivative, 293T, and p53^–/– and p53^–/– mdm2^–/– double-knockout (DKO) mouse embryonic fibroblasts (MEFs) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Raji cells treated with or without IFN- (2,000 U/ml) and IFN- (1,000 U/ml) (Sigma, St. Louis, MO), respectively, were grown in RPMI medium containing 10% or 0.2% FCS for the time indicated in the figure legends. MG132 (10 µM) (Sigma) treatment was performed for 5 to 6 h prior to harvest. The enhanced green fluorescent protein (EGFP)-tagged IFIX1 (EGFP-IFIX1) and IFIXß1 (EGFP-IFIXß1) have been previously described (18). The IFIX-N was generated using PCR primer set 5'-CCGGATCCTTAGAGATGGCAAATAACTAC (forward; containing a BamHI site) and 5'-CGGGATCCCTCAGTTGAGGAAGTGTTGG (reverse; containing a BamHI site) to amplify a 579-bp region corresponding to amino acids 1 to 193 of IFIX1. The IFIX-HIN was generated using PCR primer set 5'-CGGAATTCCAGACCTCATCATCAGCTCC (forward; containing an EcoRI site) and 5'-CGGGATCCTTACTGGATGAAACTATGCATTTC (reverse; containing a BamHI site) to amplify a 654-bp region corresponding to amino acids 179 to 397 of IFIX1. Both FLAG-tagged or EGFP-tagged IFIX-N and IFIX-HIN were generated as described before (18). GFP-p53 (gift from G. Wahl) (76), CMV-HDM2 (gift from Y. Zhang) (40), and the HDM2 mutants, i.e., HDM2(150-230) and HDM2(1-441), have been previously described (41). Plasmid DNA transfection was performed by using FuGENE 6 transfection reagent (Roche, Indianapolis, IN) according to the manufacturer's instructions. To isolate the GFP-positive cells, at 48 h after transfection, cells transfected with EGFP-IFIX1, EGFP-HIN, or EGFP empty vector were sorted out by BD FACSAria cell sorting system (Palo Alto, CA).

siRNA transfection. Electroporation was used to transfect small inhibitory RNAs (siRNAs) into cells. The IFIX siRNA, i.e., ⁶⁸⁹GGAGTAAGATGTCCAAAGA⁷⁰⁷ in exon 4 of IFIX1 (Dharmacon, Lafayette, CO), was used for transfection. The results in Fig. 8 are from a mixture of four IFIX siRNAs corresponding to amino acid sequences 689 to 707, 1,190 to 1,209, 1,246 to 1,265, and 1,486 to 1,504 of IFIX1 cDNA (Dharmacon). The nonspecific control siRNA is 5'-TAGCGACTAAACACATCAATT(dT)-3' (Dharmacon). Briefly, cells were suspended in the electroporation buffer (120 nM KCl, 0.15 mM CaCl₂, 10 mM K₂HPO₄, 6 mM glucose, 25 mM HEPES [pH 7.6], 2 mM EGTA, and 5 mM MgCl₂). The siRNAs (100 nM) were then added to the cell suspension, followed by electroporation using Nucleofector (Amaxa Biosystems, Koeln, Germany).

View larger version (23K): [in this window] [in a new window]   FIG. 8. IFIX1 mediates the IFN--induced HDM2 downregulation. (A) IFN- treatment reduces the HDM2 protein levels. Raji cells were treated with or without IFN- (2,000 U/ml) for the indicated times (0, 24, 48, and 72 h), followed by Western blotting using the antibodies against HDM2, IFIX, PKR, and -tubulin. (B) IFN- induces the expression of both IFIX1 and IFI16 proteins. Raji cells were treated with or without IFN- (2,000 U/ml) for 72 h, followed by Western blotting using the antibodies against HDM2, IFI16, IFIX, and -tubulin. (C) IFIX siRNA transfection reverses the IFN--mediated downregulation of HDM2. Raji cells growing in 0.2% FCS DMEM/F12 medium with or without IFN- treatment (2,000 U/ml) for 72 h were analyzed by Western blotting using antibodies against HDM2, IFIX, IFI16, and -tubulin (left panel). The protein expression was likewise analyzed in the Raji cells transfected with either IFIX siRNA (100 nM) or the NS siRNA (100 nM) in 0.2% FCS DMEM/F12 medium, followed by IFN- treatment (2,000 U/ml) for 72 h (right panel). (D) IFN- treatment increased the IFIX and HDM2 interaction. Cell lysates (800 µg) isolated from Raji cells treated with (+) or without (–) IFN- (2,000 U/ml) for 48 h, followed by IP with anti-HDM2 or immunoglobulin G antibody and Western blotting with anti-HDM2 and anti-IFIX antibodies.

Northern blot analysis. Northern blot analysis was performed as previously described (84).

Luciferase assays. Cells transfected with the luciferase reporter gene, PG13-LUC (a firefly luciferase gene under the control of 13 p53 responsive elements) (79), MG15-LUC (a corresponding construct with mutated p53 responsive elements), and pRL-TK (for normalizing transfection efficiency) (Promega) were harvested to measure luciferase activity using the Dual-Luciferase reporter assay system (Promega, Madison, WI) and an illuminometer (TD-20/20; Promega).

Chromatin immunoprecipitation (ChIP) assay. The modified protocol was based on that previously published (53). Briefly, IFIX1 stable MCF-7 cell lines and the vector control cell lines, X-1, X-2, and V, were fixed by 1% formaldehyde for 10 min before cell lysis. Cell lysates were subsequently sonicated, followed by centrifugation. The "input" (4% of the supernatant) was used in PCR as a positive control. The supernatant was then precleared using mouse immunoglobulin G (10 µg) for 1 h at 4°C. Protein G-agarose beads (50 µl) (Roche) were added to the supernatant and incubated for 2 h at 4°C. After centrifugation, the supernatant was then used for immunoprecipitation using anti-p53 antibody (2 µg) (NeoMarker) or an irrelevant antibody, e.g., anti-GFP antibody (2 µg) (Santa Cruz Biotech), and incubated overnight at 4°C. The protein/DNA complex was subsequently incubated with protein G-agarose beads for 2 h at 4°C. The immune complex was collected by centrifugation and then washed seven times with the following for 10 min each: twice with 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate; once with 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1% NP-40, and 0.1% SDS; twice with 50 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1% NP-40, 0.5% sodium deoxycholate, and 1 mM EDTA; and twice with TE [10 mM Tris-HCl, 1 mM EDTA] (pH 8.0) buffer. The immune complex was suspended in TE buffer with 0.25% SDS, protease K (250 µg/ml), and RNase A (50 µg/ml) (Sigma) and incubated at 37°C for 4 h and at 65°C overnight. The DNA was then extracted with phenol-chloroform and precipitated with ethanol in the presence of glycogen (20 µg) as a carrier. The precipitate was used as a template for PCR amplification. The primers that specifically amplify a 320-bp region located approximately 0.7 to 1.0 kb upstream of the human p21^CIP1 promoter are 5'-AAACCATCTGCAAATGAGGG (forward) and 5'-GAACCAATCTCCCTACACC (reverse). PCR was performed under the following conditions: 35 cycles at 94°C for 40 seconds, 56°C for 1 min, and 72°C for 40 seconds.

Mobility shift assay. Nuclear extracts isolated from MCF-7 vector control, the IFIX1 stable cell lines (X-1 and X-2), and MCF-7 cells treated with or without UV light (20 J/m²) were incubated with ³²P-labeled oligonucleotide containing p53 binding sites (p53 Nushift kit; Active Motif, Carlsbad, CA) in a binding reaction according to the manufacturer's instructions. The binding reaction was run on a 5% native polyacrylamide gel. Supershift assay was performed using the nuclear extract isolated from MCF-7 (X-1) cells incubated with or without the anti-p53 antibody provided by the p53 Nushift kit according to the manufacturer's protocol.

Cycloheximide-chase assay. Cells were cultured in six-well plates overnight. To measure the p53 turnover rate, MCF-7 vector control and the IFIX1 stable cell lines (X-1 and X-2) were treated with cycloheximide (CHX; 100 µg/ml) (Sigma) for the indicated time, followed by Western blotting using anti-p53 antibody. To measure the turnover rate, H1299 cells were cotransfected with HDM2 or the HDM2(1-441) or HDM2(C464A) (0.7 µg) mutants and IFIX1 or the vector control, pCMV-Tag2B (FLAG) (1.3 µg) (Stratagene, La Jolla, CA). Twenty-four hours after transfection, cells were treated with CHX (100 µg/ml) for the indicated time, followed by Western blotting using anti-HDM2 or anti-IFIX antibody.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

 
IFIX1 downregulates HDM2. We have previously shown that IFIX1 expression is associated with growth inhibition, suppressed transformation, and tumorigenicity (18). In searching for the mechanism underlying this phenomenon, we found that HDM2 protein levels were greatly reduced in the IFIX1-expressing MDA-MB-468 cells (which express the p53 mutant), i.e., X-1 and X-2 (18), compared with those in the vector (Fig. 1A). To test whether IFIX1 expression is the cause for HDM2 reduction, we performed an IFIX1 knockdown experiment on a low IFIX1 expression cell line, i.e., MDA-MB-468 (X-1). As shown in Fig. 1B, IFIX siRNA, a small inhibitory RNA specific for IFIX (Dharmacon), but not the control siRNA transfection rescued the reduced HDM2 level in MDA-MB-468 (X-1). This result indicates that IFIX1 may regulate the level of HDM2. However, IFIX1 expression has little effect on the HDM2 mRNA levels (Fig. 1C). Consistently, HDM2 reduction was also observed in two other cell lines, i.e., H1299 (a human nonsmall cell lung carcinoma cell line) (Fig. 2B) and 293 (a human embryonic kidney cell line) (data not shown), in a transient transfection system. These results suggest that IFIX1 regulates HDM2 protein, but not mRNA, level.

View larger version (33K): [in this window] [in a new window]   FIG. 1. IFIX1 destabilizes HDM2. (A) Inverse relationship between IFIX1 and HDM2 expression. Cell lysates isolated from IFIX1 stable MDA-MB-468 cell lines (X-1 and X-2) and the vector control cell lines (V) were analyzed by Western blotting using antibodies against HDM2, p53, IFIX, and -tubulin. (B) IFIX1 is responsible for HDM2 downregulation. MDA-MB-468 (X-1) cells were transfected with IFIX siRNA (100 nM) or NS siRNA (100 nM). Forty-eight hours after transfection, the expression levels of HDM2, IFIX1, p53, and -tubulin were analyzed by Western blotting. (C) IFIX1 has little effect on the steady-state mRNA levels of HDM2 in MDA-MB-468 cells. Total RNA (10 µg) isolated from the parental MDA-MB-468 (C), the IFIX stable cell lines (X-1 and X-2), and the empty vector transfected cells (V) was analyzed by Northern blotting using HDM2, p53, or IFIX1 cDNA as a probe. The 18S and 28S rRNAs are shown as loading controls. (D) IFIX1 destabilizes HDM2. H1299 cells were cotransfected with HDM2 (0.7 µg) and the empty vector (V) (1.3 µg) or FLAG-IFIX1 (IFIX1) (1.3 µg). Twenty-four hours posttransfection, cells were treated with CHX (100 µg/ml). Cell lysates were isolated at 0, 15, and 30 min after CHX treatment for Western blotting using antibodies against HDM2, IFIX, and -tubulin. A representative experiment is shown. (E) The amount of HDM2 protein at zero time point was arbitrarily set at 100%. The percentage of HDM2 protein remaining was determined using Bio-Rad software. The results obtained from three independent experiments are shown.

View larger version (40K): [in this window] [in a new window]   FIG. 2. IFIX1 promotes the ubiquitination of HDM2. (A) IFIX1 downregulates HDM2 through proteasome-mediated degradation. The IFIX stable MDA-MB-468 cell lines (X-1 and X-2) and the vector control cells (V) were treated with a proteasome inhibitor, MG132 (10 µM), for 6 h prior to harvest. Cell lysates were analyzed by Western blotting using anti-HDM2, anti-IFIX, and anti--tubulin. (B) H1299 cells were transfected with EGFP-tagged IFIX1 (EGFP-IFIX1) or EGFP vector. The GFP-positive cells with (+) or without (–) MG132 treatment were collected by FACS, followed by Western blotting using antibodies against HDM2, IFIX, and -tubulin. (C) IFIX1 induces the polyubiquitination of HDM2. H1299 cells were cotransfected with HDM2 (1.5 µg), hemagglutinin (HA)-ubiquitin (1 µg) (left panel) or myc-tagged ubiquitin (K48R) (1 µg) (right panel), and IFIX1 (1) (0 [–], 1.5, and 3.5 µg, left panel; 3.5 µg, right panel). Cells were treated with MG132 (10 µM) 6 h prior to harvest at 48 h posttransfection. Cell lysates were immunoprecipitated using anti-HDM2 antibody and analyzed by Western blotting using anti-HA, anti-HDM2, anti-myc, or anti-IFIX antibody. (D) The increase of the ubiquitinated HDM2 levels (n-fold) was calculated based on two independent experiments using Bio-Rad software. (E and F) The E3 ligase activity is required for the IFIX1-mediated HDM2 destabilization. The HDM2(1-441) (E) or HDM2(C464A) (F) (0.7 µg) mutant was cotransfected into H1299 cells with the empty vector (V) (1.3 µg) or FLAG-IFIX1 (IFIX1) (1.3 µg). CHX-chase assay and Western blotting were carried out as described in the legend to Fig. 1D.

IFIX1 destabilizes HDM2 protein.

IFIX1 promotes the ubiquitination of HDM2. To determine whether the IFIX1-mediated HDM2 destabilization and degradation depends on the proteasome machinery, the IFIX1 stable MDA-MB-468 cell lines and the vector control cells were treated with a proteasome inhibitor, MG132. As shown in Fig. 2A, MG132 treatment completely restored the HDM2 level in the IFIX1 stable cells compared with no treatment (Fig. 1A). A similar observation was observed in the MG132-treated H1299 cells transiently transfected with EGFP-IFIX1 (Fig. 2B). These results clearly indicate that proteasome machinery is required for the IFIX1-mediated HDM2 downregulation.

Since ubiquitinated proteins are targeted for proteasome-mediated degradation (35) and HDM2 is ubiquitinated by its own E3 ubiquitin ligase activity (23, 38), it is possible that IFIX1 may destabilize HDM2 by promoting its ubiquitination. To test this possibility, we determined the effect of IFIX1 on the levels of ubiquitinated HDM2. H1299 cells were cotransfected with HDM2, HA-tagged ubiqutin, and increasing amounts of IFIX1, followed by IP using anti-HDM2 antibody and Western blotting using anti-HA, anti-HDM2, and anti-IFIX antibodies. As shown in Fig. 2C (left panel), IFIX1 increases the levels of ubiquitinated HDM2 in a dose-dependent manner. The results obtained from two independent experiments are presented (Fig. 2D). Interestingly, the presence of IFIX1 in the HDM2 immunocomplex suggests that IFIX1 interacts with HDM2 (Fig. 2C, lower panel). The high molecular mass (>150 kDa) of HDM2 suggests that IFIX1 may promote polyubiquitination of HDM2. Since the polyubiquitin chains formed at the lysine (K)-48 residue of ubiquitin are critical for proteasome-mediated proteolysis (10), we cotransfected H1299 cells with HDM2, IFIX1, and a myc-tagged ubiquitin mutant, i.e., Ub-K48R (which is unable to form polyubiquitin chains). As shown in Fig. 2C (right panel), IFIX1 failed to induce the high-molecular-weight ubiquitinated HDM2. These results suggest that IFIX1 promotes polyubiquitination of HDM2 and are consistent with the observations that IFIX1 destabilizes HDM2 through proteasome-mediated degradation (Fig. 1D and E and 2A and B).

Since HDM2 is the substrate of its own E3 ligase activity (23, 38), it raises a possibility that IFIX1 may destabilize HDM2 through the E3 ligase activity of HDM2. To test this possibility, we first performed a CHX-chase experiment to determine the effect of IFIX1 on the turnover rate of the RING finger deletion mutant, i.e., 1-441 (in which E3 ligase domain is deleted) (41). As expected, the 1-441 mutant is very stable (Fig. 2E, left panel) compared with the wild-type HDM2 (Fig. 1D, left panel). However, IFIX1 has no effect on the turnover rate of the 1-441 mutant (Fig. 2E, right panel). This result suggests that the RING finger domain of HDM2 is required for the IFIX1-mediated destabilization. The cysteine residue at position 464 (C464) located in the RING finger domain of HDM2 is important for self-ubiquitination (23, 38). Therefore, mutation of C464 to alanine (C464A) abolishes the E3 ligase activity of HDM2. To specifically test whether E3 ligase activity is required for IFIX1 to destabilize HDM2, we performed a CHX-chase assay to determine the IFIX1 effect on the stability of the C464A mutant. As shown in Fig. 2F (left panel), the C464A mutant is relatively stable compared with the wild-type HDM2 (Fig. 1D, left panel). Importantly, IFIX1 has no effect on the turnover rate of C464A mutant (Fig. 2F, right panel). These data strongly suggest that the E3 ligase activity is required for the IFIX1-mediated HDM2 destabilization and also rule out the possibility that IFIX1 may interact with an unknown E3 ligase protein that trans ubiquitinates HDM2.

The IFIX effect on HDM2 and p53 autoregulatory loop. HDM2 and p53 form an autoregulatory loop in which HDM2 destabilizes p53 and p53 activates HDM2 transcription. IFIX1 drastically downregulates HDM2 in p53-deficient cells, such as MDA-MB-468, H1299, and 293 (Fig. 1A and 2B; data not shown). However, little change in the HDM2 protein levels was observed in IFIX1 stable MCF-7 cells (expressing wild-type p53) (Fig. 3A, top panel). The induction of p53 (Fig. 3A) leads to the increase of HDM2 mRNA levels in these cells (Fig. 3C, top panel). These results support the notion that IFIX1 cross talks with the HDM2-p53 autoregulatory loop by promoting HDM2 degradation, leading to p53 stabilization. The elevated p53 levels, in turn, increase the HDM2 levels. The net result of these two opposing effects may be responsible for the apparent little change in the HDM2 levels in cells expressing IFIX1. To further confirm this result, we employed HCT116 (a human colorectal carcinoma cell line) and its p53-null derivative, HCT116(p53^–/–), in which both p53 alleles were deleted by homologous recombination (8). Both cell lines were transfected with either EGFP-IFIX1 or EGFP control vector. Cell lysates isolated from the GFP-positive cells were analyzed by Western blotting. As shown in Fig. 3B (left panel), similar to that observed in the IFIX1 stable MCF-7 cells (Fig. 3A), IFIX1 expression increases p53 levels but has little effect on HDM2 levels in HCT116 cells. In contrast, IFIX1 expression resulted in a drastic reduction of HDM2 in HCT116(p53^–/–) cells (Fig. 3B, right panel) as observed in other p53-deficient cells (Fig. 1A and 2B).

View larger version (29K): [in this window] [in a new window]   FIG. 3. IFIX1 stabilizes p53 protein. (A) IFIX1 exerts different effects on the p53 and HDM2 levels in p53-expressing cells. Total cell lysates isolated from the IFIX1 stable MCF-7 cell lines (X-1 and X-2) and the vector control (V) cell lines were analyzed by Western blotting using antibodies against HDM2, p53, IFIX, and -tubulin. (B) The p53 status influences the IFIX1 effect on HDM2 levels. HCT116 and HCT116(p53–/–) cells were transfected with EGFP vector or EGFP-IFIX1. Forty-eight hours after transfection, the GFP-positive cells were collected using FACS. Cell lysates were analyzed by Western blotting using antibodies against HDM2, p53, IFIX, and -tubulin. (C) IFIX1 induces the steady-state HDM2 mRNA level but has little effect on p53 mRNA levels in MCF-7 cells. Total RNA (10 µg) isolated from the parental MCF-7 (C) and the stable cell lines transfected with the empty vector (V) or IFIX1 expression vector (X-1 and X-2) was analyzed by Northern blotting using HDM2, p53, or IFIX1 cDNA as a probe. The 18S and 28S rRNAs are shown as loading controls. (D) IFIX1 increases p53 protein stability. The IFIX1 stable MCF-7 (X-1 and X-2) and the vector control (V) cells were treated with CHX (100 µg /ml) for the time indicated. Cell lysates were analyzed for the expression of p53 and -tubulin. (E and F) Depletion of IFIX1 reduces p53 and p21CIP1 expression levels. The IFIX1 stable MCF-7 cell line, X-1, was transfected with siRNA specific to IFIX (IFIX) (100 nM) or NS siRNA (100 nM). Forty-eight hours after transfection, the expression levels of p53, IFIX1, p21CIP1, and -tubulin were analyzed by Western blotting.

IFIX1 increases p53 protein stability.

The causative effect of IFIX1 on p53 induction was further confirmed by an IFIX1 knockdown experiment using IFIX siRNA. As shown in Fig. 3E, the IFIX siRNA transfection specifically reduces p53 protein levels in a low-IFIX1-expressing MCF-7 cell line, X-1, compared with transfection with the nonspecific scramble control (NS) siRNA. As expected, p53 reduction by IFIX siRNA correlates with decreased expression of a p53 transcriptional target, p21^CIP1 (Fig. 3F). These results indicate that IFIX1 can stabilize and activate p53 in the IFIX1 MCF-7 stable cell lines.

IFIX1 activates the p53-mediated transcription. IFIX1 induces p53 and increases the steady-state mRNA levels of p53 target genes, e.g., the HDM2 gene (Fig. 3C), and p21^CIP1 (18) expression, suggesting that IFIX1 induces p53-mediated transcriptional activity. To test that possibility, we transfected H1299 with PG13-LUC, a luciferase reporter construct containing multiple p53 binding sites (79), or MG15-LUC, a corresponding construct containing mutated p53 binding sites. Since H1299 is p53 null (86), it is necessary to cotransfect a p53 expression vector to observe the increase of p53-mediated transcription. We found that IFIX1 readily enhanced the p53-mediated transcriptional activity of PG13-LUC (but not MG15-LUC) in a dose-dependent manner (Fig. 4A). This result indicates that IFIX1 indeed activates the p53-mediated transcription. We then tested whether IFIX1 also increases p53 DNA binding. We employed a mobility shift assay in which the ³²P-labeled oligonucleotides containing p53 DNA binding sites were incubated with the nuclear extracts isolated from the IFIX1 stable MCF-7 cell lines (X-1 and X-2) and the vector control cells. The p53/DNA complex was resolved by a native gel electrophoresis. As shown in Fig. 4B (left panel), the p53 DNA binding activity is strongly enhanced in X-1 and X-2 cells compared with that in the control cells. The p53 DNA binding activity induced by DNA-damaging agents, such as UV light, serves as a positive control. The protein/DNA complex is p53 specific since incubation with anti-p53 antibody in the X-1 nuclear extract diminishes this complex. The increase of p53 DNA binding correlates well with an increase of p53 in the nuclear extracts isolated from the X-1 and X-2 cells (Fig. 4B, right panel).

View larger version (21K): [in this window] [in a new window]   FIG. 4. IFIX1 activates p53-mediated transcription. (A) IFIX1 augments the p53-mediated transcriptional activity. H1299 cells were transfected with 0.3 µg of PG13-LUC or MG15-LUC with or without p53 (0.01 µg) and IFIX1 (0.845 and 1.69 µg). pRL-TK (0.05 µg) was cotransfected to normalize transfection efficiency. Cells were harvested 24 h after transfection, and the luciferase activity was measured using a dual luciferase assay (Promega). The relative luciferase activity was obtained by setting the normalized activity of PG13-LUC or MG15-LUC at 1. (B) IFIX1 enhances p53 DNA binding activity. Nuclear extract (7.5 µg) was incubated with 32P-labeled oligonucleotide containing p53 binding sites prior to electrophoretic mobility shift assay according to the manufacturer's instructions (p53 Nushift kit; Geneka) (left panel). MCF-7 cells treated with (+) or without (–) UV light (20 J/m2) serve as a positive control. Nuclear extract isolated from X-1 cells was incubated with (+) or without (–) the anti-p53 antibody (Ab) in the binding reactions to indicate the specific p53/DNA complex (arrow). The nuclear extracts used in the mobility shift assay were analyzed for the expression levels of p53 and IFIX1 by Western blotting (right panel). (C) Increased p53 binding to the p21CIP1 promoter in IFIX1 stable cells. A ChIP assay was performed in the vector control (V) and the IFIX1 stable MCF-7 (X-1 and X-2) cells. The primer pair that specifically amplifies a 320-bp region of p21CIP1 promoter was used to analyze the DNA immunoprecipitated by either anti-p53 antibody or a control anti-GFP antibody. The input DNA used for the ChIP assay was likewise amplified to indicate equal loading.

HDM2 downregulation is required for the IFIX1-mediated p53 induction and activation. Next, we wanted to determine whether the activation of p53 by IFIX1 is through repression of MDM2. To do so, we cotransfected a p53^–/– MEF and a p53^–/– mdm2^–/– DKO MEF with GFP-tagged p53 and increasing amounts of IFIX1. The exogenous p53 is induced by IFIX1 in the p53^–/– MEF in a dose-dependent manner, presumably caused by increasing p53 stability in these cells (Fig. 5A, left panel). As expected, p53 is more stable in the DKO MEF (Fig. 5A, right panel). However, IFIX1 has no effect on the p53 levels in these cells (Fig. 5A, right panel). Consistent with these observations, IFIX1 activates p53-mediated transcription in a dose-dependent manner in the p53^–/– MEF but not in the DKO MEF (Fig. 5B). Notably, p53 drastically enhances p53-mediated transcription in the DKO MEF in the absence of IFIX1. It is likely due to the higher p53 levels in the DKO MEF than those in the p53^–/– MEF (Fig. 5A). Together, these results support the idea that IFIX1 induces p53 levels and its transcriptional activity by targeting primarily HDM2.

View larger version (23K): [in this window] [in a new window]   FIG. 5. mdm2 is required for p53 induction and nuclear accumulation by IFIX1. (A) mdm2 is required for the increased p53 protein expression by IFIX1. The p53–/– MEF or DKO MEF was transfected with GFP-p53 (0.1 µg) and increasing amounts of IFIX1 (0, 1, and 2 µg). Twenty-four hours posttransfection, cell lysates were analyzed by Western blotting using antibodies against p53, IFIX1, and -tubulin. (B) mdm2 is required for the p53-mediated transcriptional activation by IFIX1. PG13-LUC (0.3 µg) was cotransfected with p53 (0.01 µg) with or without increasing amounts of IFIX1 (0.845 µg and 1.69 µg) into the p53–/– MEF or DKO MEF. pRL-TK (0.05 µg) was cotransfected to normalize transfection efficiency. Cells were harvested 24 h after transfection, and the luciferase activity was measured using a dual luciferase assay. The relative luciferase activity was obtained by setting the normalized activity of PG13-LUC alone at 1. (C) IFIX1 promotes p53 nuclear localization. GFP-p53 was transfected into the IFIX1 stable MCF-7 (X-1 and X-2) and the vector control (V) cells. Twenty-four hours after transfection, the number of cells in which GFP-p53 localized in both nucleus and cytoplasm (C+N) or predominantly in the nucleus (N) was counted. Average results were obtained from two independent experiments. V (C+N, 54.55% ± 3.45%; N, 45.45% ± 3.45%); X-1 (C+N, 36.1% ± 1.9%; N, 63.9% ± 1.9%); and X-2 (C+N, 21.15% ± 1.85%; N, 78.85% ± 1.85%). (D) IFIX1 has little effect on p53 nuclear localization in the presence of the HDM2(C464A) mutant. GFP-p53 (0.25 µg) was cotransfected into the H1299 cells with HDM2 (0.75 µg) and IFIX1 or empty vector (1.25 µg). Twenty-four hours after transfection, the number of cells in which GFP-p53 localized in both nucleus and cytoplasm or predominantly in the nucleus was counted. Average results were obtained from two independent experiments: V and HDM2 (C+N, 49% ± 3.4%; N, 51% ± 3.4%); IFIX1 and HDM2 (C+N, 29% ± 0.4%; N, 71% ± 0.4%); V and C464A (C+N, 31.7% ± 3.1%; N, 68.3% ± 3.1%); and IFIX1 and C464A (C+N, 27% ± 1.6%; N, 73% ± 1.6%). On average, more than 80 GFP-positive cells were counted in each transfection experiment.

IFIX1 promotes p53 nuclear accumulation.

IFIX1 interacts with HDM2. The interaction between IFIX1 and HDM2 was detected by a co-IP experiment (Fig. 2C). To confirm this interaction, 293T cells were transfected with HDM2 and EGFP vector, EGFP-IFIX1, or EGFP-IFIXß1. The protein-protein interaction was examined by IP using anti-HDM2 antibody and followed by Western blotting with either anti-GFP or anti-HDM2 antibody. Clear interactions between HDM2 and IFIX1 and between HDM2 and IFIXß1 were detected (Fig. 6A). A reciprocal experiment using anti-GFP antibody to pull down EGFP-IFIX1 and EGFP-IFIXß1 further confirmed the presence of these complexes (Fig. 6B). These data strongly suggest that HDM2 interacts with IFIX1 or IFIXß1. We have attempted to investigate a possible interaction between HDM2 and the smallest IFIX isoform, IFIX1 (18). However, we found that IFIX1 could be extracted using only SDS-containing lysis buffer (data not shown). Therefore, it is not feasible to detect such an interaction using the standard IP protocol. The interaction between IFIX1 and HDM2 was also observed in cells cotransfected with FLAG-tagged IFIX1 and HDM2 into 293T cells (data not shown). Consistently, we also found the interaction between IFIX1 and HDM2 in the IFIX1 stable MCF-7 cell lines, X-1 and X-2, but not in the vector control cells (Fig. 6C). Together, these results strongly indicate that IFIX1 interacts with HDM2.

View larger version (57K): [in this window] [in a new window]   FIG. 6. IFIX1 interacts with HDM2. (A) HDM2 interacts with IFIX1 and IFIXß1. 293T cells were cotransfected with HDM2 (2.5 µg) and EGFP vector (vector) (2.5 µg), EGFP-tagged IFIX1 (1) (2.5 µg), or IFIXß1 (ß1) (2.5 µg). Forty-eight hours posttransfection, cell lysates (500 µg) were immunoprecipitated with an anti-HDM2 antibody, and Western blotting was performed using an anti-GFP or anti-HDM2 antibody. (B) A reciprocal experiment that used anti-GFP antibody for IP and Western blotting with anti-IFIX or anti-HDM2 antibodies. (C) IFIX1 interacts with HDM2 in the IFIX1 stable cell lines. Cell lysates (600 µg) isolated from the IFIX1 stable MCF-7 cell lines (X-1 and X-2) or the empty vector cells (V) were immunoprecipitated using anti-HDM2 antibody and analyzed by Western blotting with anti-IFIX or anti-HDM2 antibody. (D) The HDM2(1-441) mutant interacts with IFIX1. 293T cells were transfected with HDM2 or the HDM2(1-441) mutant and EGFP-IFIX1 (1) or EGFP empty vector (V), followed by IP with anti-HDM2 antibody and Western blotting with either anti-HDM2 or anti-GFP antibody. (E and F) Amino acid region 150 to 230 of HDM2 interacts with IFIX1. 293T cells were cotransfected with HDM2 or the HDM2(150-230) mutant and EGFP-IFIX1 (1) or EGFP empty vector (E) or FLAG-IFIX1 (1) or FLAG empty vector (F), followed by IP/Western blotting with the indicated antibodies. An arrowhead indicates the HDM2 band (F). The untransfected 293T cells served as controls (C). (G) A summary of IFIX1 binding by HDM2 and the HDM2(150-230) and HDM2(1-441) mutants. (H and I) The HIN domain of IFIX1 interacts with HDM2. (H) 293T cells transfected with HDM2 and EGFP empty vector, EGFP-IFIX1, EGFP-IFIX-N (N), or EGFP-IFIX-HIN (HIN), followed by IP with anti-GFP antibody (left panel) or anti-HDM2 antibody (right panel) and Western blotting with anti-HDM2 or anti-GFP antibody. Untransfected 293T cells served as controls. (I) A summary of HDM2 binding by IFIX1, IFIXß1, IFIX-N, and IFIX-HIN.

IFIX1 binds to amino acid region 150 to 230 of HDM2. To map the HDM2 region binding to IFIX1, we cotransfected 293T cells with EGFP-IFIX1 and HDM2 mutants, e.g., RING finger deletion (1-441) and deletion of amino acids 150 to 230 deletion (150-230) (Fig. 6G) (41), followed by IP/Western blotting. Like the wild-type HDM2 (Fig. 6A-B), the HDM2(1-441) mutant can readily interact with IFIX1 (Fig. 6D). Since the anti-HDM2 antibody used in IP recognizes that the epitope resides within amino acid region 150 to 230 of HDM2, it is therefore not suitable for immunoprecipitating HDM2(150-230). Instead, we cotransfected 293T cells with either EGFP-IFIX1 or FLAG-IFIX1 and HDM2 or HDM2(150-230), followed by IP with anti-GFP antibody (Fig. 6E) or anti-FLAG antibody (Fig. 6F), respectively. The HDM2 and IFIX1 interaction serves as a positive control. While the expression levels of HDM2(150-230) and IFIX1 are detectable by direct Western blotting, there is no HDM2(150-230) protein present in the IFIX1 immunocomplex. This result suggests that amino acid region 150 to 230 of HDM2 is required for IFIX1 binding (Fig. 6G).

The HIN region of IFIX1 interacts with HDM2. IFIX1 differs from IFIXß1 at the C-terminal sequence (18). The observation that both isoforms interact with HDM2 (Fig. 6A and B) suggests that the C-terminal sequence of IFIX1 is dispensable for HDM2 binding. To map the HDM2 binding domain of IFIX1, we generated deletion mutants that express either the N-terminal PYD domain (IFIX-N) or the HIN domain (IFIX-HIN). Although IFIX-N is clearly localized in the nucleus, IFIX-HIN, which lacks the putative nuclear localization signal (NLS) in the N-terminal domain (18), localizes in both nuclear and cytoplasmic compartments. Howbeit, nuclear localization appears dominant (data not shown). To determine their ability to bind HDM2, we cotransfected 293T cells with HDM2 and EGFP, EGFP-tagged IFIX1, IFIX-N, or IFIX-HIN, followed by IP using anti-GFP (Fig. 6H, left panel) or anti-HDM2 (Fig. 6H, right panel) antibody and Western blotting with either anti-HDM2 or anti-GFP antibody. These results show that IFIX-HIN, but not IFIX-N, is sufficient to bind HDM2 (Fig. 6I).

The HIN domain is sufficient to downregulate HDM2 and induce p53. The observation that IFIX-HIN is sufficient to bind HDM2 (Fig. 6H) prompted us to test whether IFIX-HIN regulates HDM2 expression. We transfected 293 cells with EGFP-tagged IFIX-HIN or EGFP empty vector, followed by fluorescence-activated cell sorter (FACS) analysis to enrich the GFP-positive cells. The HDM2 protein levels of the GFP-positive cells were analyzed by Western blotting. As shown in Fig. 7A, IFIX-HIN transfection is sufficient to reduce the endogenous HDM2 levels compared to transfection with EGFP vector. As expected, MG132 treatment stabilizes HDM2 expression. However, unlike those of IFIX1 (Fig. 2B) and IFIX-N (data not shown), which are stable proteins, IFIX-HIN expression levels increase with MG132 treatment (Fig. 7A). This result suggests that IFIX-HIN is a relatively unstable protein and is susceptible to degradation by proteasome machinery.

View larger version (19K): [in this window] [in a new window]   FIG. 7. IFIX-HIN is sufficient to downregulate HDM2. (A) IFIX-HIN downregulates HDM2 expression. 293T cells were transfected with EGFP empty vector (EGFP) or EGFP-IFIX-HIN. MG132 (10 µM) treatment started at 5 h before harvest. Cell lysates isolated from the GFP-positive cells were analyzed by Western blotting using antibodies against HDM2, EGFP, and -tubulin. (B to D) IFIX-HIN induces p53 and p21CIP1. H1299 cells were transfected with p53 (0.1 µg) and increasing amounts (0.5, 1.0, and 1.8 µg) of the FLAG-tagged IFIX1 (B), IFIX-HIN (C), or IFIX-N (D), followed by Western blotting using antibodies against p53, IFIX (B), FLAG (C and D), p21CIP1, and -tubulin at 24 h posttransfection. (E) IFIX1 induces p21CIP1 mRNA expression. H1299 cells were cotransfected with p53 (0.5 µg) and 5.5 µg of FLAG-tagged empty vector (V), IFIX1 (1), IFIX-HIN (HIN), or IFIX-N (N). At 24 h posttransfection, total RNA (10 µg) isolated from these cells was analyzed by Northern blotting using p21CIP1 or IFIX cDNA as a probe. The 18S and 28S rRNAs served as loading controls.

IFIX mediates the HDM2 downregulation by IFN-. IFIX1 is an IFN-inducible protein (18). We tested whether the regulation of HDM2 by IFIX1 can be observed in the IFN-inducible system. We then examined the effect of IFN on HDM2 expression in Raji cells (a human Burkitt's lymphoma cell line in which p53 is mutated) (20) because IFIX1 expression can be readily induced by IFN- in these cells (18). Interestingly, we observed a biphasic effect on the HDM2 protein levels in response to the IFN- treatment (Fig. 8A). In particular, the HDM2 levels gradually increase between 0 and 48 h and decrease sharply at 72 h of treatment. Notably, the endogenous IFIX (which may include 1 and 2 isoforms) protein expression becomes detectable at 48 h and persists through 72 h of treatment. As a positive control for the IFN- responsiveness, the same membrane was probed with an antibody against a known IFN-inducible protein, PKR (39). As expected, the PKR levels increase in response to IFN- treatment, indicating that the IFN pathway is activated (Fig. 8A). This result shows that IFN indeed regulates HDM2 expression. In particular, IFN downregulates HDM2 at 72 h of treatment.

To examine the role of IFIX in the IFN--mediated HDM2 downregulation, we looked for a condition in which IFIX, but not other HIN-200 proteins, e.g., IFI16, MNDA, and AIM2, could be readily induced by IFN-. Under the normal condition with 10% FCS, we found that the expression levels of both IFIX and IFI16 are induced by IFN- (Fig. 8B). The expression of MNDA was not detectable regardless of IFN- treatment (data not shown). The expression of AIM2 is not clear under this condition because the anti-AIM2 antibody is not available. Interestingly, we found that IFIX but not IFI16 could be induced by IFN- in low serum with 0.2% FCS (Fig. 8C, left panel). Importantly, the IFN--induced IFIX expression remains correlated with HDM2 downregulation under this condition. Thus, the low serum condition provides us a unique opportunity to determine the role of IFIX in IFN--induced HDM2 downregulation. To ensure the specificity of IFIX siRNA, a mixture of four IFIX siRNAs (see Materials and Methods) was transfected into Raji cells, followed by IFN- treatment. We show that IFIX siRNAs transfection reduces IFIX but that it has little effect on IFI16 expression (Fig. 8C, right panel). Importantly, IFIX knockdown by IFIX siRNAs increases the expression level of HDM2 compared to transfection with NS siRNA (Fig. 8C, right panel). This result indicates that IFIX plays an essential role in the IFN--mediated HDM2 downregulation.

To test whether the interaction between IFIX and HDM2 also occurs in the IFN-inducible system, we performed IP/Western blot analysis on Raji cells treated with IFN- for 48 h (at this time point, HDM2 levels are not reduced) (Fig. 8A). As shown in Fig. 8D, a physiological interaction between IFIX and HDM2 was detected in these cells. The induction of IFIX by IFN- correlates well with an increase of interaction between IFIX and HDM2 (Fig. 8D).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In this report, we present evidence suggesting that IFIX1 functions as a negative regulator of HDM2. Consequently, IFIX1 positively regulates p53 by stabilizing p53, leading to an increase of p53-dependent transcription and nuclear accumulation. Importantly, these IFIX1 effects on p53 require HDM2 downregulation, suggesting that HDM2 is the primary target of IFIX1.

IFIX1 interacts with HDM2 and promotes its ubiquitination and degradation (Fig. 1, 2, and 6). The mechanism by which IFIX1 promotes HDM2 ubiquitination is not clear. HIN-200 proteins are not known to possess enzymatic activity. It has been postulated that these proteins may function as nuclear scaffolds to modulate gene transcription through interaction with other proteins (12). Therefore, it is possible that IFIX1, when binding to HDM2, may simultaneously compromise the binding of certain HDM2 interacting proteins that negatively regulate the ubiquitination of HDM2, e.g., p14ARF (70, 82), MDMX (32, 74), TSG101 (50), and HAUSP (51). Thus, it is conceivable that IFIX1 may disrupt these interactions and restore the E3 ligase activity of HDM2, resulting in an increase of ubiquitination. In addition, posttranslational modifications, such as sumoylation, acetylation, and phosphorylation, are also known to regulate the E3 ligase activity of HDM2 (9, 58). It is possible that IFIX1 may alter certain modifications of HDM2 and tip the balance to favoring ubiquitination. HDM2 is known to be a nucleocytoplasmic shuttling protein (68). Moreover, since IFIX1 binds to HDM2 through amino acid region 150 to 230, which contains nuclear export signals/NLSs (Fig. 6G), it is also possible that IFIX1 may regulate HDM2 ubiquitination and degradation by altering the cellular localization of HDM2.

Emerging evidence has suggested a cross talk between the IFN signaling pathway and the p53 tumor suppressor pathway. For example, it was shown that IFN-/ß transcriptionally activates p53 (77). In contrast, certain IFN-inducible proteins were shown to regulate p53 posttranscriptionally. For instance, PKR not only activates p53 transcription (87) but also binds to the C terminus of p53 and phosphorylates serine 392 (14). In turn, PKR upregulates p53-mediated transcription (13). IFI16 binds to p53 and augments the p53-mediated transcriptional activation (26, 43). This interaction between IFI16 and p53 may contribute to the ability of IFI16 to sensitize cells to p53-dependent apoptosis induced by -irradiation (26). Another example is p202a, which inhibits p53-mediated transcriptional activity by presumably being a component of the p53 protein complex through binding to p53 binding protein 1 (15). Although IFIX1 colocalizes with p53 in the nucleus (data not shown), we have not detected a physical association between IFIX1 and p53 despite intensive efforts to look for such interaction (data not shown). Additional experiments, such as gel filtration analysis, are needed to verify this observation. However, it remains possible that the interactions between IFIX1 and HDM2 and between p53 and HDM2 may exist as mutually exclusive complexes. If this hypothesis is proven valid, it may suggest that, unlike that between PKR, IFI16, and p202a, the interaction between IFIX1 and p53 may not be necessary for the IFIX1-induced p53 stabilization and transcriptional activation. Rather, our data suggest that HDM2 but not p53 is the primary target of IFIX1. This conclusion is supported by the observation that ectopic p53 can be stabilized and activated by IFIX1 only in the p53^–/– MEF but not in the DKO MEF (Fig. 5A and B).

The nuclear localization of IFIX-N is somewhat expected since a putative NLS, ¹³⁴LGPQKRKK, resides within the N-terminal region of IFIX1 (18). However, unlike IFIX1, which forms nuclear specks (18), IFX-N localizes throughout the nucleus (data not shown). This result suggests that the unique C-terminal 52-amino-acid region of IFIX1 may be responsible for the nuclear speck localization. On the other hand, the attenuated nuclear localization of IFIX-HIN (data not shown) suggests that the N-terminal NLS is required for the exclusive nuclear localization of IFIX1. It also suggests that other NLSs may exist to direct IFIX-HIN to the nucleus. Two highly charged regions, e.g., ²⁵⁹LKRKFIKKR and ³⁰⁶RRAKKIPK, reside within the HIN domain and may represent such NLSs. Alternatively, it is possible that IFIX-HIN may be shuttled into the nucleus by interacting with unknown nuclear protein.

We mapped the HDM2 binding region to the HIN domain of IFIX1 (Fig. 6H). Remarkably, like IFIX1, IFIX-HIN is sufficient to downregulate HDM2 and to induce p53 and p21^CIP1 (Fig. 7C and E). This result is consistent with our previous finding that p21^CIP1 induction was observed in cells expressing IFIX1 and IFIXß1 but not IFIX1, which lacks the HIN domain (18). Thus, the N-terminal PYD domain and the C-terminal sequence of IFIX1 appear to be dispensable for downregulating HDM2. It is thus possible that IFIX-HIN may be sufficient to destabilize HDM2. Although experiments have been performed to test this possibility, the instability of IFIX-HIN protein (Fig. 7A) has become a challenge in this effort. Perhaps an exclusively nucleus-localized IFIX-HIN, by tagging its own NLS or a heterologous NLS, may help to solve the stability issue. Nevertheless, given that IFIX-HIN is the signature motif of HIN-200 proteins, it is possible that other HIN-200 family proteins may possess a similar activity to destabilize HDM2.

We have previously shown that IFIX1 induced p21^CIP1 in cells with or without wild-type p53 (18). Although we show in this study that IFIX1 induces p21^CIP1 through p53 upregulation (Fig. 3E and F, 4C, and 7B and E), the p53-independent mechanism remains to be elucidated. Interestingly, recent reports showed that HDM2 can interact directly with p21^CIP1 protein and promotes its degradation (41, 88). Therefore, one possible p53-independent posttranslational mechanism underlying p21^CIP1 induction may be through HDM2 downregulation by IFIX1.

In addition to their role in innate and adaptive immunity (5), IFNs also possess proapoptosis, antiangiogenesis, and antiproliferation activities, which have been the basis for using IFNs to treat human malignancies (34, 69). The antitumor activity of IFN is likely attributed to the tumor suppressor functions of certain IFN-inducible proteins (34, 48). HIN-200 genes have been implicated as tumor suppressors due to their loss or reduced expression in certain human malignancies (for recent reviews, see references 2 and 54). IFIX1, a novel member of the human HIN-200 gene family, is downregulated in breast cancer, and its expression is associated with growth inhibition and tumor suppression (18). Here, we present a mechanism for the IFIX1-mediated antitumor activity. Our data show that IFIX1 destabilizes HDM2. IFIX1 does so by binding to HDM2 and promoting its ubiquitination and degradation. Consequently, p53 is stabilized and the p53-responsive gene products, such as p21^CIP1, are activated, leading to growth inhibition. Therefore, the cross talk between the IFN-IFIX1 pathway and the HDM2-p53 pathway may contribute in part to the overall IFN-mediated antitumor activity in certain human cancers.

	ACKNOWLEDGMENTS

 
This work was supported by a Susan G. Komen Breast Cancer Foundation grant and an Institutional Research grant from the University of Texas, M. D. Anderson Cancer Center (to D.-H.Y), by grant CA095441 from the NIH (to H.L.), and by Cancer Center Core grant CA16672. Y.D. is the recipient of a postdoctoral fellowship from the Department of Defense (DAMD17-02-1-0451).

We thank Yanping Zhang for helpful discussion. We also thank Mien-Chie Hung, Li-Kuo Su, Naoto Ueno, Bert Vogelstein, Geoffrey Wahl, and Yanping Zhang for their generous gift of reagents used in this study.

	FOOTNOTES

 
* Corresponding author. Mailing address: Department of Molecular and Cellular Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Phone: (713) 792-3677. Fax: (713) 794-0209. E-mail: dyan{at}mdanderson.org.

	REFERENCES

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Albrecht, M., D. Choubey, and T. Lengauer. 2005. The HIN domain of IFI-200 proteins consists of two OB folds. Biochem. Biophys. Res. Commun. 327:679-687.[CrossRef][Medline]

2. Asefa, B., K. D. Klarmann, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and J. R. Keller. 2004. The interferon-inducible negative regulator of cell growth. Blood Cells Mol. Dis. 32:155-167.[CrossRef][Medline]

3. Azzimonti, B., M. Pagano, M. Mondini, M. De Andrea, G. Valente, G. Monga, M. Tommasino, P. Aluffi, S. Landolfo, and M. Gariglio. 2004. Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index. Histopathology 45:560-572.[CrossRef][Medline]

4. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.[Medline]

5. Biron, C. A., and G. C. Sen. 2001. Interferons and other cytokines, p. 321-351. In D. M. Knipe, P. M. Howley, D. E. Griffin, et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.

6. Bochkarev, A., and E. Bochkareva. 2004. From RPA to BRCA2: lessons from single-stranded DNA binding by the OB-fold. Curr. Opin. Struct. Biol. 14:36-42.[CrossRef][Medline]

7. Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563-568.[CrossRef][Medline]

8. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.[Abstract/Free Full Text]